Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “underperform” rating restated by Bank of America in a research note issued on Friday. They presently have a $68.00 price target on the biopharmaceutical company’s stock. Bank of America‘s price target would suggest a potential downside of 38.64% from the stock’s previous close.

ICPT has been the subject of several other reports. Raymond James reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday. Credit Suisse Group reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, February 12th. JMP Securities upgraded Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $75.00 to $175.00 in a research note on Wednesday, January 30th. Jefferies Financial Group upped their price objective on Intercept Pharmaceuticals to $150.00 and gave the company a “buy” rating in a research note on Monday, January 28th. Finally, Needham & Company LLC upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research note on Thursday, January 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $153.94.

ICPT stock opened at $110.82 on Friday. The company has a market capitalization of $3.29 billion, a PE ratio of -7.71 and a beta of 1.88. The company has a debt-to-equity ratio of 3.83, a current ratio of 5.98 and a quick ratio of 5.98. Intercept Pharmaceuticals has a 12-month low of $58.03 and a 12-month high of $133.74.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 1,313 shares of the stock in a transaction on Monday, January 7th. The stock was sold at an average price of $104.93, for a total transaction of $137,773.09. Following the sale, the insider now owns 18,807 shares in the company, valued at $1,973,418.51. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Christian Weyer sold 1,343 shares of the company’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $113.78, for a total transaction of $152,806.54. Following the completion of the transaction, the executive vice president now directly owns 17,162 shares in the company, valued at approximately $1,952,692.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 762,130 shares of company stock worth $80,106,185. Company insiders own 4.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC increased its holdings in shares of Intercept Pharmaceuticals by 3.6% in the fourth quarter. Squarepoint Ops LLC now owns 3,399 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 118 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Intercept Pharmaceuticals by 14.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 183 shares during the period. LPL Financial LLC increased its holdings in shares of Intercept Pharmaceuticals by 0.3% in the fourth quarter. LPL Financial LLC now owns 74,815 shares of the biopharmaceutical company’s stock worth $7,541,000 after purchasing an additional 254 shares during the period. Advisor Group Inc. increased its stake in Intercept Pharmaceuticals by 63.5% in the fourth quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 287 shares during the last quarter. Finally, Strs Ohio increased its stake in Intercept Pharmaceuticals by 30.0% in the fourth quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 300 shares during the last quarter. 63.48% of the stock is currently owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

See Also: How prevalent are 12b-1 fees?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.